Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

variants have previously been described in patients with myopathy, lactic acidosis and sideroblastic anemia 2 (MLASA2). encodes the mitochondrial tyrosyl-tRNA synthetase, which is responsible for conjugating tyrosine to its cognate mt-tRNA for mitochondrial protein synthesis. Here we describe 14 individuals from 11 families presenting with sideroblastic anemia and variants that we identified using a sideroblastic anemia gene panel or exome sequencing. The phenotype of these patients ranged from MLASA to isolated congenital sideroblastic anemia. As in previous cases, inter- and intra-familial phenotypic variability was observed, however, this report includes the first cases with isolated sideroblastic anemia and patients with biallelic variants that have no clinically ascertainable phenotype. We identified ten novel variants and three previously reported variants. amino-acylation assays of five novel missense variants showed that three had less effect on the catalytic activity of YARS2 than the most commonly reported variant, p.(Phe52Leu), associated with MLASA2, which may explain the milder phenotypes in patients with these variants. However, the other two missense variants had a more severe effect on YARS2 catalytic efficiency. Several patients carried the common c.572 G>T, p.(Gly191Val) variant (minor allele frequency =0.1259) in with a rare deleterious variant. We have previously shown that the p.(Gly191Val) variant reduces YARS2 catalytic activity. Consequently, we suggest that biallelic variants, including severe loss-of-function alleles in of the common p.(Gly191Val) variant, should be considered as a cause of isolated congenital sideroblastic anemia, as well as the MLASA syndromic phenotype.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6269294PMC
http://dx.doi.org/10.3324/haematol.2017.182659DOI Listing

Publication Analysis

Top Keywords

sideroblastic anemia
32
pgly191val variant
12
variants
10
sideroblastic
8
isolated sideroblastic
8
anemia
8
myopathy lactic
8
lactic acidosis
8
acidosis sideroblastic
8
anemia variants
8

Similar Publications

[The 511th case: severe anemia with increased ringed sideroblasts].

Zhonghua Nei Ke Za Zhi

September 2025

Department of Hematology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China.

This report describes the case of a 43-year-old male presenting with severe anemia (hemoglobin, HGB 35 g/L). A comprehensive evaluation encompassing bone marrow morphology (24% ring sideroblasts), genetic testing (SF3B1-negative), iron metabolism studies (ferritin 1 179 μg/L), and imaging (liver MRI T2* value 1.1 ms) was performed for diagnosis, treatment planning, and assessment of outcomes.

View Article and Find Full Text PDF

IntroductionMLASA (myopathy, lactic acidosis and sideroblastic anemia) is a rare, autosomal recessive mitochondrial disorder. Symptom onset typically occurs in childhood and differs considerably in disease severity. Congenital-onset disease is uncommon.

View Article and Find Full Text PDF

[Emerging perspectives on sideroblastic anemia].

Rinsho Ketsueki

August 2025

Department of Laboratory Medicine and Infectious Diseases, Iwate Medical University School of Medicine.

Sideroblastic anemias (SAs) represent a diverse group of congenital and acquired disorders, characterized by anemia and the presence of ring sideroblasts in the bone marrow. Congenital sideroblastic anemia (CSA) arises from genetic mutations that disrupt heme and iron metabolism within mitochondria. The most common form of CSA is X-linked sideroblastic anemia (XLSA), caused by mutations in the erythroid-specific aminolevulinate synthase 2 (ALAS2) gene, a key enzyme in the heme biosynthesis pathway in erythroid cells.

View Article and Find Full Text PDF

Objective Vitamin B6 (VB6) deficiency leads to microcytic hypochromic anemia with ringed sideroblasts. Sideroblastic anemia due to VB6 deficiency is an important differential diagnosis to consider in cases with sideroblastic anemia associated with myelodysplastic syndrome (MDS). However, VB6 screening is underutilized in Japan as it is not covered by the national health insurance system, potentially leading to low screening rates.

View Article and Find Full Text PDF

Vitamin B6 (VB6) is a vital coenzyme for δ-aminolevulinic acid synthase (ALAS) in heme biosynthesis. We report a 49-year-old male with severe microcytic anemia and ringed sideroblasts initially diagnosed as myelodysplastic syndrome (MDS). VB6 deficiency, attributed to long-term amoxapine use, was identified.

View Article and Find Full Text PDF